AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 2, 2022
Scientists have discovered DNA-damaging molecules made by gut bacteria that may help explain why people with inflammatory bowel disease (IBD) have higher rates of colorectal cancer than those without the condition.
Pharmaceutical Technology
DECEMBER 14, 2022
Bacteria naturally develop resistance to antibiotics over time, through genetic mutation, horizontal gene transfer between bacteria, or because of selective pressure. Virus versus bacteria. Phages are viruses of bacteria. Secondly, the relationships between phages and bacteria are very specific.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
MARCH 18, 2022
Columbia Engineering researchers report that they have developed a “cloaking” system that temporarily hides therapeutic bacteria from immune systems, enabling them to more effectively deliver drugs to tumors and kill cancer cells in mice. Using Bacteria For Therapy. Some trials had to be terminated due to severe toxicity.”
pharmaphorum
OCTOBER 7, 2020
Originally discovered in bacteria as a defense mechanism against pathogens, CRISP/Cas9 has made it possible to make exquisitely detailed and precise alterations to DNA sequences on demand, and as a tool for molecular biology has already transformed research into diseases and drug discovery. million) Nobel Prize award. “In
Camargo
JULY 27, 2021
It is a comprehensive term which encompasses a large variety of therapy products including viral and bacterial vectors, plasmid DNA, human gene editing technology, and patient-specific cellular gene therapy. Additionally, gene editing allows us either to remove or to modify harmful genes. Formulation Considerations.
Roots Analysis
FEBRUARY 27, 2024
Currently, product licensing agreements, technology licensing agreements, research and development agreements and clinical trial agreements are the common types of partnerships inked by developers that are currently focused on the development of ADCs pipeline. In nature, they are made by a group of bacteria known as actinomycetes.
Delveinsight
JULY 26, 2021
Often the bacteria develop antibiotic resistance to certain drugs, leaving it non-effective for the usage the second time in the case of recurrence of the infection that occurs in approximately 30-35% of the uUTI cases, therefore, leaving a serious dearth of the new antibiotics. coli bacteria called FimH.
Expert insights. Personalized for you.
187 
Let's personalize your content